GTBP · GT Biopharma, Inc.

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2025, financial statements, raised substantial doubt about the Company’s ability to continue as a going concern.”